Restrictive cardiomyopathy: definition and diagnosis. (21st October 2022)

• Record Type: Journal Article
• Authors: Rapezzi, Claudio; Aimo, Alberto; Barison, Andrea; Emdin, Michele; Porcari, Aldostefano; Linhart, Ales; Keren, Andre; Merlo, Marco; Sinagra, Gianfranco
• Is Part Of: European heart journal. Volume 43:Number 45(2022)
• Page Start: 4679
• Page End: 4693
• Publication Date: 2022-10-21
• Subjects: Restrictive cardiomyopathy -- RCM -- Classification -- Myocardial disease -- Amyloidosis; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehac543
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Restrictive cardiomyopathy (RCM) is a heterogeneous group of diseases characterized by restrictive left ventricular pathophysiology, i.e. a rapid rise in ventricular pressure with only small increases in filling volume due to increased myocardial stiffness. More precisely, the defining feature of RCM is the coexistence of persistent restrictive pathophysiology, diastolic dysfunction, non-dilated ventricles, and atrial dilatation, regardless of ventricular wall thickness and systolic function. Beyond this shared haemodynamic hallmark, the phenotypic spectrum of RCM is wide. The disorders manifesting as RCM may be classified according to four main disease mechanisms: (i) interstitial fibrosis and intrinsic myocardial dysfunction, (ii) infiltration of extracellular spaces, (iii) accumulation of storage material within cardiomyocytes, or (iv) endomyocardial fibrosis. Many disorders do not show restrictive pathophysiology throughout their natural history, but only at an initial stage (with an evolution towards a hypokinetic and dilated phenotype) or at a terminal stage (often progressing from a hypertrophic phenotype). Furthermore, elements of both hypertrophic and restrictive phenotypes may coexist in some patients, making the classification challenge. Restrictive pathophysiology can be demonstrated by cardiac catheterization or Doppler echocardiography. The specific conditions may usually be diagnosed based on clinical data, 12-lead electrocardiogram, echocardiography, nuclear medicine, or cardiovascular magnetic resonance, but further investigations may be needed, up to endomyocardial biopsy and genetic evaluation. The spectrum of therapies is also wide and heterogeneous, but disease-modifying treatments are available only for cardiac amyloidosis and, partially, for iron overload cardiomyopathy. Graphical Abstract: Graphical Abstract Proposed classification of restrictive cardiomyopathy according to myocardial histology, the genetic basis and the transient or permanent nature of restriction. APOA, apolipoprotein A; ATTRv, variant amyloid transthyretin amyloidosis; EMF, endomyocardial fibrosis; HES, hypereosinophilic syndrome; PRKAG2, protein kinase AMP-activated non-catalytic subunit gamma 2.